Accentia Biopharmaceuticals Majority-Owned Subsidiary Biovest International, Inc. Receives Rare Disease Designation From European Drug Agency For Follicular Non-Hodgkin’s Lymphoma

TAMPA, Fla.--(BUSINESS WIRE)--A majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), Biovest International, Inc. (OTCBB:BVTI), has received notification from the Commission of the European Union on its acceptance of Biovest’s BiovaxID™ therapy for Follicular Lymphoma for entry into the European Community’s Drug Register for Rare Diseases. This designation significant offers benefits to Biovest in its development and marketing of BiovaxID™ in the European Union (EU).